|
- People With Severe Diabetes Are Cured in Small Trial of New . . .
A person’s conventional supplies for treating type 1 diabetes A single infusion of a new treatment, called zimislecel, may have cured 10 out of 12 people with the most severe form of the disease
- Zimislecel, a novel cell therapy, appears to restore islet . . .
Results from the phase 1 2 portion of the FORWARD-101 trial, which enrolled patients with type 1 diabetes with severe hypoglycemic events and impaired hypoglycemic awareness, were presented at the
- People with Severe Type 1 Diabetes are Cured in Small Trial . . .
"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times "One year later, these 10 patients no longer need insulin The other two patients need much lower doses " The experimental treatment, cal
- Off-the-shelf stem cell therapy for type 1 diabetes yields . . .
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions You can reach Liz on Signal at LizC 22 Twelve people with type 1 diabetes who
- Oral Semaglutide Significantly Improves Cardiovascular . . .
Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s A recent study found that oral semaglutide offers meaningful cardiovascular benefits for people with type 2 diabetes, lowering risk by 14% Results from the Semaglutide Cardiovascular Outcomes Trial (SOUL) were unveiled as a late-breaking symposia at American Diabetes Asso
- Son’s diabetes diagnosis sent scientist on quest for cure
Over the decades, Melton and his colleagues made a series of discoveries that laid the groundwork for a new treatment to restore insulin production in patients with Type 1 diabetes Melton compares this stem cell-derived islet therapy to “educating” a stem cell and its descendants — introducing the protein signals that trigger or inhibit
- Weekly Insulins and Therapeutic Burden in Type 2 Diabetes
The recent approval of newer glucagon-like peptide-1 (GLP-1) receptor agonists administered weekly for the treatment of type 2 diabetes has provided an alternative regimen; however, the use of
|
|
|